{"id":829337,"date":"2025-03-25T07:43:05","date_gmt":"2025-03-25T11:43:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-ost-her2-immunotherapy-for-osteosarcoma-featured-in-upcoming-movie-shelter-me-the-cancer-pioneers\/"},"modified":"2025-03-25T07:43:05","modified_gmt":"2025-03-25T11:43:05","slug":"os-therapies-ost-her2-immunotherapy-for-osteosarcoma-featured-in-upcoming-movie-shelter-me-the-cancer-pioneers","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-ost-her2-immunotherapy-for-osteosarcoma-featured-in-upcoming-movie-shelter-me-the-cancer-pioneers\/","title":{"rendered":"OS Therapies\u2019 OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers"},"content":{"rendered":"

<\/p>\n

OS Therapies\u2019 OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers<\/i><\/b><\/p>\n

Documentary focusing on canine comparative oncology will premiere at the Los Angeles AMC Century City on April 3rd<\/sup><\/i><\/p>\n

NEW YORK–(BUSINESS WIRE<\/a>)–
\nOS Therapies (NYSE-A: OSTX) (\u201cOS Therapies\u201d or \u201cthe Company\u201d), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that OST-HER2 is featured in the upcoming movie Shelter Me: The Cancer Pioneers<\/i>. The movie offers a look into canine comparative oncology, a field that compares treatment of cancers in dogs to those in people, and covers developing treatments for rare forms of cancer. OST-HER2 is an immunotherapy for osteosarcoma using a HER2 bioengineered form of the bacteria Listeria monocytogenes to trigger a strong immune response against cancer cells expressing HER2. The movie will premiere on April 3, 2025 at AMC Century City in Los Angeles and will be available to stream through the PBS app and on PBS.org starting in May.\n<\/p>\n

\n\u201cOur team is dedicated to advancing a treatment for osteosarcoma and are proud to see our immunotherapy in Shelter Me: The Cancer Pioneers<\/i>,\u201d stated OS Therapies\u2019 CEO Paul Romness. \u201cComparative oncology is an important area of research for us because of the striking genetic homology of over 96% between human and canine osteosarcoma.\u201d OST-HER2 is an investigational drug and is not currently approved to treat osteosarcoma or any other disease.\n<\/p>\n

Shelter Me: The Cancer Pioneers<\/i> also features leading scientists at the National Cancer Institute \/ National Institutes of Health, the University of Pennsylvania, the University of Illinois, the University of Wisconsin, and Colorado State University. It is part of an Emmy Award-winning PBS series, Shelter Me,<\/i> that celebrates the life-changing relationships between people and animals.\n<\/p>\n

\nA trailer of the movie can be viewed here<\/a>.\n<\/p>\n

About OS Therapies<\/b><\/p>\n

\nOS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company’s lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the US Food & Drug Administration and Fast-Track and Orphan Drug designations from the US FDA and European Medicines Agency. The Company positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a Biologics Licensing Application (BLA) to the US FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma.\n<\/p>\n

\nIn addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC<\/i> (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company’s proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit www.ostherapies.com<\/a>.\n<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nStatements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as “anticipate,” “expect,” “intend,” “may,” “will,” “should” or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management\u2019s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the approval of OST-HER2 by the US FDA and grant of a priority review voucher and other risks and uncertainties described in \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations\u201d in the Company\u2019s registration statement on Form S-1 filed with the Securities and Exchange Commission (the \u201cSEC\u201d) on November 12, 2024, as amended on November 27, 2024, and other subsequent documents we file with the SEC, including but not limited to our Quarterly Reports on Form 10-Q. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250325194230\/en\/<\/a><\/span><\/p>\n

OS Therapies Contact Information:
\n<\/b>
Jack Doll
\n
571.243.9455
\n
Irpr@ostherapies.com<\/a><\/p>\n

https:\/\/x.com\/OSTherapies
\n<\/a>
https:\/\/www.instagram.com\/ostherapies\/
\n<\/a>
https:\/\/www.facebook.com\/OSTherapies\/
\n<\/a>
https:\/\/www.linkedin.com\/company\/os-therapies\/<\/a><\/p>\n

KEYWORDS:<\/b> United States North America New York<\/p>\n

INDUSTRY KEYWORDS:<\/b> Research Entertainment Film & Motion Pictures Pharmaceutical Oncology Consumer TV and Radio Science Veterinary Biotechnology Health Pets Other Science<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

OS Therapies\u2019 OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers Documentary focusing on canine comparative oncology will premiere at the Los Angeles AMC Century City on April 3rd NEW YORK–(BUSINESS WIRE)– OS Therapies (NYSE-A: OSTX) (\u201cOS Therapies\u201d or \u201cthe Company\u201d), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that OST-HER2 is featured in the upcoming movie Shelter Me: The Cancer Pioneers. The movie offers a look into canine comparative oncology, a field that compares treatment of cancers in dogs to those in people, and covers developing treatments for rare forms of cancer. OST-HER2 is an immunotherapy for osteosarcoma using a HER2 bioengineered form of the bacteria Listeria monocytogenes to trigger a … <\/p>\n

Continue reading “OS Therapies\u2019 OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-829337","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nOS Therapies\u2019 OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-ost-her2-immunotherapy-for-osteosarcoma-featured-in-upcoming-movie-shelter-me-the-cancer-pioneers\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OS Therapies\u2019 OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"OS Therapies\u2019 OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers Documentary focusing on canine comparative oncology will premiere at the Los Angeles AMC Century City on April 3rd NEW YORK–(BUSINESS WIRE)– OS Therapies (NYSE-A: OSTX) (\u201cOS Therapies\u201d or \u201cthe Company\u201d), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that OST-HER2 is featured in the upcoming movie Shelter Me: The Cancer Pioneers. The movie offers a look into canine comparative oncology, a field that compares treatment of cancers in dogs to those in people, and covers developing treatments for rare forms of cancer. OST-HER2 is an immunotherapy for osteosarcoma using a HER2 bioengineered form of the bacteria Listeria monocytogenes to trigger a … Continue reading "OS Therapies\u2019 OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-ost-her2-immunotherapy-for-osteosarcoma-featured-in-upcoming-movie-shelter-me-the-cancer-pioneers\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-25T11:43:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250325194230r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/os-therapies-ost-her2-immunotherapy-for-osteosarcoma-featured-in-upcoming-movie-shelter-me-the-cancer-pioneers\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/os-therapies-ost-her2-immunotherapy-for-osteosarcoma-featured-in-upcoming-movie-shelter-me-the-cancer-pioneers\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"OS Therapies\u2019 OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers\",\"datePublished\":\"2025-03-25T11:43:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/os-therapies-ost-her2-immunotherapy-for-osteosarcoma-featured-in-upcoming-movie-shelter-me-the-cancer-pioneers\\\/\"},\"wordCount\":906,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/os-therapies-ost-her2-immunotherapy-for-osteosarcoma-featured-in-upcoming-movie-shelter-me-the-cancer-pioneers\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250325194230r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/os-therapies-ost-her2-immunotherapy-for-osteosarcoma-featured-in-upcoming-movie-shelter-me-the-cancer-pioneers\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/os-therapies-ost-her2-immunotherapy-for-osteosarcoma-featured-in-upcoming-movie-shelter-me-the-cancer-pioneers\\\/\",\"name\":\"OS Therapies\u2019 OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/os-therapies-ost-her2-immunotherapy-for-osteosarcoma-featured-in-upcoming-movie-shelter-me-the-cancer-pioneers\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/os-therapies-ost-her2-immunotherapy-for-osteosarcoma-featured-in-upcoming-movie-shelter-me-the-cancer-pioneers\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250325194230r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-03-25T11:43:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/os-therapies-ost-her2-immunotherapy-for-osteosarcoma-featured-in-upcoming-movie-shelter-me-the-cancer-pioneers\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/os-therapies-ost-her2-immunotherapy-for-osteosarcoma-featured-in-upcoming-movie-shelter-me-the-cancer-pioneers\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/os-therapies-ost-her2-immunotherapy-for-osteosarcoma-featured-in-upcoming-movie-shelter-me-the-cancer-pioneers\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250325194230r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250325194230r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/os-therapies-ost-her2-immunotherapy-for-osteosarcoma-featured-in-upcoming-movie-shelter-me-the-cancer-pioneers\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OS Therapies\u2019 OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"OS Therapies\u2019 OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-ost-her2-immunotherapy-for-osteosarcoma-featured-in-upcoming-movie-shelter-me-the-cancer-pioneers\/","og_locale":"en_US","og_type":"article","og_title":"OS Therapies\u2019 OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers - Market Newsdesk","og_description":"OS Therapies\u2019 OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers Documentary focusing on canine comparative oncology will premiere at the Los Angeles AMC Century City on April 3rd NEW YORK–(BUSINESS WIRE)– OS Therapies (NYSE-A: OSTX) (\u201cOS Therapies\u201d or \u201cthe Company\u201d), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that OST-HER2 is featured in the upcoming movie Shelter Me: The Cancer Pioneers. The movie offers a look into canine comparative oncology, a field that compares treatment of cancers in dogs to those in people, and covers developing treatments for rare forms of cancer. OST-HER2 is an immunotherapy for osteosarcoma using a HER2 bioengineered form of the bacteria Listeria monocytogenes to trigger a … Continue reading \"OS Therapies\u2019 OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-ost-her2-immunotherapy-for-osteosarcoma-featured-in-upcoming-movie-shelter-me-the-cancer-pioneers\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-25T11:43:05+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250325194230r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-ost-her2-immunotherapy-for-osteosarcoma-featured-in-upcoming-movie-shelter-me-the-cancer-pioneers\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-ost-her2-immunotherapy-for-osteosarcoma-featured-in-upcoming-movie-shelter-me-the-cancer-pioneers\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"OS Therapies\u2019 OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers","datePublished":"2025-03-25T11:43:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-ost-her2-immunotherapy-for-osteosarcoma-featured-in-upcoming-movie-shelter-me-the-cancer-pioneers\/"},"wordCount":906,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-ost-her2-immunotherapy-for-osteosarcoma-featured-in-upcoming-movie-shelter-me-the-cancer-pioneers\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250325194230r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-ost-her2-immunotherapy-for-osteosarcoma-featured-in-upcoming-movie-shelter-me-the-cancer-pioneers\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-ost-her2-immunotherapy-for-osteosarcoma-featured-in-upcoming-movie-shelter-me-the-cancer-pioneers\/","name":"OS Therapies\u2019 OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-ost-her2-immunotherapy-for-osteosarcoma-featured-in-upcoming-movie-shelter-me-the-cancer-pioneers\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-ost-her2-immunotherapy-for-osteosarcoma-featured-in-upcoming-movie-shelter-me-the-cancer-pioneers\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250325194230r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-03-25T11:43:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-ost-her2-immunotherapy-for-osteosarcoma-featured-in-upcoming-movie-shelter-me-the-cancer-pioneers\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-ost-her2-immunotherapy-for-osteosarcoma-featured-in-upcoming-movie-shelter-me-the-cancer-pioneers\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-ost-her2-immunotherapy-for-osteosarcoma-featured-in-upcoming-movie-shelter-me-the-cancer-pioneers\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250325194230r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250325194230r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/os-therapies-ost-her2-immunotherapy-for-osteosarcoma-featured-in-upcoming-movie-shelter-me-the-cancer-pioneers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"OS Therapies\u2019 OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829337","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=829337"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829337\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=829337"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=829337"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=829337"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}